Congratulations Dr. Kassoum Kayentao and the entire L9LS study team for today's publication of the L9LS monoclonal antibody (mAb) clinical trial that was conducted in children 6-10 years old in Mali. The mAb was given subcutaneously, which simplified its administration. The mAb achieved 67-77% efficacy against clinical malaria over six months. Our Malaria Molecular Diagnostic Laboratory performed RT-PCR testing in support of the trial. Looking forward to continuing to work with this great team to help protect children and other vulnerable populations in the fight against malaria.
0 Comments
|
Lab PostUpdates about lab activities, papers and other insights! Archives
April 2024
Categories |